References
1. Liu F., Long X., Zhang B., Zhang W., Chen X., Zhang Z. ACE 2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020; 18 (9): 2128-30.e2. DOI: https://doi.org/10.1016/j.cgh.2020.04.040
2. Muniangi-Muhitu H., Akalestou E., Salem V., Misra S., Oliver N.S., Rutter G.A. COVID-19 and diabetes: a complex bidirectional relationship. Front Endocrinol (Lausanne). 2020; 11: 582936. DOI: https://doi.org/10.3389/fendo.2020.582936
3. Zhou Z., Sun B., Huang S., Zhu C., Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc Diabetol. 2020; 19: 102. DOI: https://doi.org/10.1186/s12933-020-01085-6
4. Danne T., Nimri R., Battelino T., Bergenstal R.M., Close K.L., DeVries J.H., et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40 (12): 1631-40. DOI: https://doi.org/10.2337/dc17-1600
5. Battelino T., Danne T., Bergenstal R.M., Amiel S.A., Beck R., Biester T., et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42 (8): 1593-603. DOI: https://doi.org/10.2337/dci19-0028
6. Ametov A.S., Kamynina L.L., Nazhmudinova P.K. Clinical aspects of the use of continuous glycemic monitoring in diabetology. Russkiy medit-sinskiy zhurnal [Russian Medical Journal]. 2013; 21 (28): 1401-4. (in Russian)
7 Chernikova N.A., Kamynina L.L., Ametov A.S. The cardiometabolic assessment of the glycemic variability in patients with diabetes mellitus: the role of the glucocardiomonitoring. Kardiologiya [Cardiology]. 2020; 60 (5): 100-6. DOI: https://doi.org/10.18087/cardio.2020.5.n902 (in Russian)
8. Bonora B.M., Boscari F., Avogaro A., Bruttomesso D., Fadini G.P. Gly-caemic control among people with type 1 diabetes during lockdown for the SARS-CoV-2 outbreak in Italy. Diabetes Ther. 2020; 11 (6): 1369-79. DOI: https://doi.org/10.1007/s13300-020-00829-7
9. Prabhu Navis J., Leelarathna L., Mubita W., et al. Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England. Acta Diabetol. 2020; 1-7 DOI: https://doi.org/10.1007/s00592-020-01614-5
10. Ametov A.S., Kamynina L.L. Contemporary interpretation of the oral glucose tolerance test with 75g glucose (diagnostic and prognostic approaches). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2012; 1 (1): 45-9. (in Russian)
11. Dalan R., Bornstein S.R., El-Armouche A., Rodionov R.N., Markov A., Wie-lockx B., et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res. 2020; 52 (5): 257-63. DOI: https://doi.org/10.1055/a-1155-0501
12. Valencia I., Peiro C, Lorenzo 0., Sanchez-Ferrer C.F., Eckel J., Romacho T. DPP4 and ACE 2 in diabetes and COVID-19: therapeutic targets for cardiovascular complications? Front Pharmacol. 2020; 11: 1161. DOI: https://doi.org/10.3389/fphar.2020.01161
13. Samanta J., Gupta R., Singh M.P., Patnaik I., Kumar A., Kochhar R. Coro-navirus disease 2019 and the pancreas. Pancreatology. 2020; 20 (8): 1567-75. DOI: https://doi.org/10.1016/j.pan.2020.10.035
14. Caballero A.E., Ceriello A., Misra A., et al. COVID-19 in people living with diabetes: an international consensus. J Diabetes Complications. 2020; 34 (9): 107671. DOI: https://doi.org/10.1016/j.jdiacomp.2020.107671
15. Alessi J., de Oliveira G.B., Schaan B.D., Telo G.H. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndr. 2020; 12: 80. DOI: https://doi.org/10.1186/s13098-020-00583-7
16. RECOVERY Collaborative Group; Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020; July 17 DOI: https://doi.org/10.1056/NEJMoa2021436
17 Scheen A.J. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab. 2020; 46 (6): 423-6. DOI: https://doi.org/10.1016/j.diabet.2020.07.006
18. Sharma S., Ray A., Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res Clin Pract. 2020; 164: 108183. DOI: https://doi.org/10.1016/j.diabres.2020.108183
19. Bramante C., Ingraham N., Murray T., Marmor S., Hoversten S., Gronski J., et al. Observational study of metformin and risk of mortality in patients hospitalized with COVID-19. Version 2. medRxiv. 2020; Jun 28. DOI: https://doi.org/10.1101/2020.06.19.20135095
20. Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47 (3): 193-9. DOI: https://doi.org/10.1007/s00592-009-0109-4
21. Rubino F., Amiel S.A., Zimmet P., et al. New-onset diabetes in COVID-19. N Engl J Med. 2020; 383 (8): 789-90. DOI: https://doi.org/10.1056/NEJMc2018688
22. Alvarado-Vasquez N. Could a family history of type 2 diabetes be a risk factor to the endothelial damage in the patient with COVID-19? Med Hypotheses. 2020; 2020: 110378. DOI: https://doi.org/10.1016/j.mehy.2020.110378